Semaglutide in Atlanta, GA

1. Medical consultation and evaluation. A licensed provider takes a full medical history, reviews every medication and supplement you take, discusses your weight history and prior attempts, and asks specifically about thyroid cancer, MEN 2, pancreatitis, gallbladder disease, kidney disease, gastrointestinal disorders, diabetic retinopathy, eating disorders, and pregnancy or plans to conceive.
2. Baseline measurements and any laboratory work indicated by your history — which may include metabolic and kidney function panels, blood glucose or A1c, or other testing your provider determines is appropriate. What is ordered depends on your individual clinical picture.
3. An informed-consent discussion covering the boxed warning, the contraindications, the common and serious side effects, the fact that the medication is an adjunct to diet and exercise, and the likelihood of weight regain if treatment stops.
4. If treatment is appropriate, a prescription and a titration plan, along with instruction on injection technique, storage, and what to do about a missed dose.
5. A plan for the non-medication side of treatment: protein targets, resistance training, hydration, and a follow-up cadence.

Change is gradual, unfolding over months as the dose is titrated. In clinical trials of semaglutide for chronic weight management, participants saw average total body weight reduction in the mid-teens percent range over roughly 68 weeks, combined with diet and exercise. Those are trial averages, not promises: individual results vary widely, some people respond minimally, and no outcome is guaranteed.

1. Semaglutide is given as a subcutaneous injection once weekly, on the same day each week, with or without food. You can change the day of the week if needed, provided the interval between doses is at least the minimum your prescriber specifies.
2. Treatment starts at a low introductory dose. That first dose is not intended to be an effective weight-management dose — it exists to let your gut adapt.
3. The dose is increased stepwise at intervals set by your prescriber, typically after several weeks at each level, and only if you are tolerating the current dose. Titration is not a race, and it is common and appropriate to hold at a dose, slow the schedule, or step back down if side effects are significant.
4. Inject into subcutaneous fat in the abdomen, thigh, or upper arm. Rotate sites and rotate the specific spot within a site each week to avoid irritation and lipohypertrophy. Do not inject into muscle or vein.
5. The needle is very fine and short, and most people describe the injection as a brief pinch or as barely noticeable. Mild redness, itching, or a small bump at the site can occur and typically settles quickly.
6. Follow the storage instructions for your specific product, and never share a pen or needle with anyone else, even with a new needle attached.

Semaglutide is dosed once weekly by subcutaneous injection, on the same day each week. Treatment begins at a low introductory dose that is deliberately below the effective range, and the dose is increased in steps at intervals set by your prescriber — typically after several weeks at each level, and only if the current dose is being tolerated. Some people settle at a maintenance dose below the maximum, which is a perfectly legitimate outcome. Titration is individualized: holding a dose, extending the interval between increases, or stepping back down are all normal clinical responses to side effects, not failures.

This is best understood as a long-term treatment decision rather than a short course. Obesity is managed as a chronic condition, and the appetite-regulating effect of the medication lasts only as long as the medication is present. Studies of GLP-1 therapy have consistently shown that appetite tends to return and that substantial weight regain is common after discontinuation — an important reality to weigh before starting, and one reason nutrition, protein intake, resistance training, and sustainable habits are built into treatment from day one rather than added at the end. If and when you and your provider decide to stop or taper, do it as a planned conversation with a maintenance strategy in place, not by simply stopping.

1. Follow-up visits on the cadence your provider sets — more frequently early on and around dose increases, then at longer intervals once you are stable. Follow-up is where the dose gets adjusted and where problems get caught.
2. Manage nausea proactively: smaller portions, eating slowly and stopping at the first sense of fullness, avoiding large fatty or greasy meals, and avoiding lying down immediately after eating. Nausea is usually dose-dependent and often improves as the body adapts to a given dose. Tell your provider if it does not.
3. Hydrate deliberately. Reduced appetite often means reduced fluid intake, and dehydration — particularly alongside vomiting or diarrhea — is the mechanism by which this class can cause acute kidney injury.
4. Prioritize protein at every meal and do resistance training at least twice weekly. Weight lost on any calorie deficit includes lean muscle mass, and protecting muscle is one of the most important things you can do while on a GLP-1. This is not optional advice.
5. Continue the reduced-calorie diet and increased physical activity that the medication is prescribed as an adjunct to. In the clinical trials, the medication was always given alongside lifestyle intervention, never instead of it.
6. Report promptly: severe or persistent abdominal pain, persistent vomiting or an inability to keep fluids down, symptoms of a gallbladder attack, a lump or swelling in the neck, hoarseness, or trouble swallowing. Also report low blood sugar symptoms if you take insulin or a sulfonylurea.
7. Tell every clinician who treats you that you are on a GLP-1 receptor agonist — especially before any surgery, endoscopy, or procedure involving sedation or anesthesia, because delayed gastric emptying has been associated with reports of aspiration risk and your anesthesia plan may need to change.

• Nausea — the most frequently reported effect, usually dose-dependent and often improving as the body adapts to each dose level
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain, cramping, or bloating
• Acid reflux, heartburn, or belching
• Fatigue
• Headache, dizziness, and injection-site reactions such as redness, itching, or a small bump

• Severe, persistent abdominal pain — especially pain that radiates to the back, with or without vomiting. This can be pancreatitis. Stop the medication and seek emergency care.
• Persistent vomiting or diarrhea, an inability to keep fluids down, or signs of dehydration such as dark urine, markedly reduced urination, dizziness on standing, or confusion.
• Symptoms of a gallbladder attack: pain in the upper right abdomen, fever, yellowing of the skin or eyes (jaundice), or clay-colored stools.
• A lump or swelling in the neck, persistent hoarseness, trouble swallowing, or shortness of breath — report these to a physician promptly given the boxed warning regarding thyroid C-cell tumors.
• Signs of a serious allergic reaction: rash or hives, swelling of the face, lips, tongue, or throat, or difficulty breathing or swallowing. Call 911.
• Symptoms of low blood sugar — shakiness, sweating, confusion, rapid heartbeat, blurred vision — particularly if you also take insulin or a sulfonylurea.

• Pancreatitis (inflammation of the pancreas) — uncommon but serious; the classic presentation is severe, persistent abdominal pain that may radiate to the back, with or without vomiting. Stop the medication and seek medical care immediately.
• Gallbladder disease, including gallstones and cholecystitis — risk is associated with GLP-1 therapy itself and with rapid weight loss generally; may require surgery.
• Acute kidney injury, typically driven by dehydration from persistent vomiting or diarrhea.
• Boxed warning — thyroid C-cell tumors: in rodent studies, GLP-1 receptor agonists including semaglutide caused thyroid C-cell tumors, including medullary thyroid carcinoma. Whether this occurs in humans has not been determined. The medication is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Aspiration under anesthesia — because the drug delays gastric emptying, food may remain in the stomach longer than expected during sedation or general anesthesia. There have been reports of aspiration risk. Always tell your surgeon and anesthesiologist that you take a GLP-1 receptor agonist, well before any procedure.
• Hypoglycemia — uncommon with semaglutide alone in people without diabetes, but a genuine risk when combined with insulin or sulfonylureas, which may need dose adjustment by the prescriber.
• Other reported risks include worsening of diabetic retinopathy in people with diabetes, increased heart rate, severe gastrointestinal reactions, gastroparesis or ileus, and serious hypersensitivity reactions.

There is no procedural downtime. A weekly subcutaneous injection takes seconds, requires no numbing, and you go straight back to your day — there is nothing to recover from in the way there is with an in-office procedure. The real story of tolerability is gastrointestinal. The days following an injection, and particularly the week or two after each dose increase, are when nausea, reflux, constipation, or fatigue are most likely to show up. For many people these are manageable and settle as the body adapts to a given dose; for some they are significant enough that the titration needs to be slowed, held, or reversed, and for a minority they are a reason to stop the medication altogether. Plan dose increases for weeks when you have some flexibility, and tell your provider what you are experiencing rather than pushing through it silently.